ライフサイエンスコーパス: no use

1 rettes (aOR 3.04, 2.11-4.40 for >=7 h use vs no use).

2 ed penicillins for >or=15 days compared with no use).

3 nfidence interval: 0.75, 0.91) compared with no use.

4 a given duration of ERT use is compared with no use.

5 ed with greater odds of current smoking than no use.

6 1.08-1.98]), compared with individuals with no use.

7 e (>3 months before start of pregnancy), and no use.

8 hat it can sometimes be ambiguous or even of no use.

9 reported comparing medical cannabis use with no use.

10 1.7 to 0.0]) for previous use, compared with no use.

11 with rate increases in inconsistent use and no use.

12 Wave 4 ENDS use: daily, nondaily, or no use.

13 py use during the 90 days before delivery vs no use.

14 h small-cell lung cancer for >4 years versus no use.

15 cases among 18,145 participants who reported no use.

16 st year only, and 1 186,501 person-years for no use.

17 utathione-related oxidative burden exposure (no use, 15.8%; irregular use, 3.8%), whereas mold (22.1%

18 per 100 000 person years were 8 (8 to 9) for no use, 18 (16 to 20) for combined oral contraception, 1

19 ence interval (CI) 0.6%-1.1%]} compared with no use [180-day absolute risk: 0.4% (95% CI 0.3%-0.5%)]:

20 re 18 (95% confidence interval 18 to 19) for no use, 39 (36 to 42) for combined oral contraception, 3

21 use with a gradual decrease to very low-dose/no use, 4) initial high-dose use with a gradual decrease

22 The addition of exogenous NO using a NO donor prevented the reduction in iNOS leve

23 re classified as "obese" (O) or "non-obese" (NO) using a BMI cut-off of 25 kg/m(2).

24 iated with higher odds of sICH compared with no use (adjusted odds ratio [AOR], 1.18 [95% CI, 1.10-1.

25 sed odds of psychosis or mania compared with no use (adjusted odds ratio=0.91, 95% CI=0.54-1.55).

26 h prescription amphetamine use compared with no use (adjusted odds ratio=2.68, 95% CI=1.90-3.77).

27 ine vaping cessation (eg, 4 to 7 d/wk use vs no use: adjusted odds ratio [aOR], 1.14; 95% CI, 0.51-2.

28 lar events by any in-trial SGLT2i use versus no use also showed no evidence of heterogeneity in the e

29 n of nitrous oxide (N(2)O) and nitric oxide (NO) using ammonia (NH(3)) as a selective reducing agent

30 from the comparisons between monotherapy and no use and between polypharmacy and no use were in line

31 marijuana use in the past 12 months (any vs no use and number of occasions used).

32 ne pouch (yes or no) and e-cigarette (yes or no) use and co-use patterns (exclusive pouch without e-c

33 vs. no use), and adjuvant tamoxifen (use vs. no use) and were compared via log-rank tests.

34 de (1 vs. 3), adjuvant chemotherapy (use vs. no use), and adjuvant tamoxifen (use vs. no use) and wer

35 ent, such information is often lacking or of no use, and epidemiological parameters must be estimated

36 .47; 95% CI, 2.78-28.25; vs among those with no use: aOR, 5.60; 95% CI, 1.97-17.06; overall interacti

37 r and harder materials, these have little to no use as bulk structural materials without appropriate

38 cannabis use at each assessment as non-use [no use at any assessment], occasional-use [use at 1-2 as

39 % reported discontinuation (ie, use at T and no use at T + 1), 6.5% initiated e-cigarettes (ie, no us

40 at T + 1), 6.5% initiated e-cigarettes (ie, no use at T and use at T + 1), and 79.2% reported persis

41 garette use (ie, daily use, nondaily use, or no use) at follow-up interview among smokers not using e

42 documented cannabis use (medical, other, and no use) based on practitioner documentation of medical c

43 Compared with no use, current use of combined oral contraception was a

44 Compared with no use, current use of progestin-only pills was associat

45 There was no use-dependent block of IFM/QQQ mutant channels with t

46 pid activation and deactivation kinetics and no use-dependent inactivation.

47 t 3 months of pregnancy, was contrasted with no use during the same time period.

48 tified 3574 azathioprine episodes and 18 700 no-use episodes, which resulted in 3374 pairs after prop

49 d 61.9 events per 1000 patient-years for the no-use episodes.

50 ine and GABA(C) receptors displays little or no use-facilitated block.

51 erson-years) compared with six events in the no-use group (8.4 events per 1000 person-years).

52 irin NSAIDs compared with those who reported no use (hazard ratio (HR) = 0.92, 95% confidence interva

53 ssociated with tobacco use, as compared with no use (hazard ratio, 1.54; 95% CI, 1.23 to 1.94; P<0.00

54 ith recent use of a statin, as compared with no use (hazard ratio, 2.89; 95% CI, 1.51 to 5.55; P=0.00

55 etection of the DAF-FM reaction product with NO using HPLC and LC-MS/MS.

56 ter the last menstrual period, compared with no use in either month, were 2.8 (95% confidence interva

57 ings of this cohort study of GLP-1 RA use vs no use in patients with MGUS and diabetes suggest the po

58 110%) in their urine than women who reported no use in the past 24 h.

59 Vaping, tobacco smoking, dual use, or no use in the past 7 days.

60 ivated by pulmonary surfactant, making it of no use in the therapy of pneumonia.

61 nal folic acid supplement use (compared with no use) in the prepregnancy period through the first tri

62 as continued use (at least 1 fill per year), no use, inconsistent use, and new use by medication type

63 iological relevance, as many pathogens sense NO using iron-sulfur proteins and will be exposed to NO

64 Compared with no use, long-term and repeated short-term oral/systemic

65 We formed 5 groups (no use, low, medium, high, and very high) based on the f

66 d risk of new-onset arrhythmia compared with no use-most pronounced in the 180 days following the ini

67 ium intake from supplements (>=1000 mg/d vs. no use: multivariable-adjusted rate ratio, 1.53 [CI, 1.0

68 oups had higher concentrations of TNE-2 than no use (n = 146; geometric mean [SD], 0.19 [1.14] nmol/m

69 ratified by baseline SGLT2i use (N = 550) or no use (N = 2,983) and randomized to semaglutide/placebo

70 ), and 5.3 for children born to mothers with no use (n = 270 198).

71 n, or both were randomized to use (n=253) or no use (n=252) of the Bleeper Sv radiation monitor.

72 ek." For omega-3 supplement use, relative to no use, no significant associations with autism diagnosi

73 f methamphetamine use relative to periods of no use (odds ratio [OR], 5.3 [95% CI, 3.4-8.3]; P < .001

74 riods of cannabis use relative to periods of no use (odds ratio, 1.13; 95% CI, 1.03-1.24).

75 models without sibling control, ever-use vs no use of acetaminophen during pregnancy was associated

76 For example, for autism, compared with no use of acetaminophen, persons with low (<25th percent

77 1,102,050 episodes of azithromycin use with no use of antibiotic agents (matched in a 1:1 ratio acco

78 a 5-day treatment episode), as compared with no use of antibiotics (rate ratio, 2.85; 95% confidence

79 s within the preceding 7 days, compared with no use of anticoagulants, was not associated with a sign

80 icantly increased risk of sICH compared with no use of anticoagulants.

81 was total control (no emesis, no nausea, and no use of antiemetic rescue medication) over the initial

82 ic/diastolic blood pressure <140/90 mmHg and no use of antihypertensive drugs).

83 o 44-year-old males and females who reported no use of antihypertensive medication.

84 history of overt cardiovascular disease, and no use of antihypertensive medication.

85 dication; blood pressure 120/</=80 mm Hg and no use of antihypertensive medication; no current smokin

86 L or higher, bodyweight less than 80 kg, and no use of antimalarial drugs over the past week.

87 (HR, 0.58; 95% CI, 0.44-0.77) compared with no use of antipsychotic medication.

88 more cost-beneficial than nonvaccination and no use of antiviral medication.

89 ength of association between statin use (vs. no use of any cholesterol-lowering drug) and the risk of

90 is of the antiepileptic drug Phenytoin, with no use of any harmful organic solvent.

91 Episodes of incident azathioprine use and no use of any thiopurine were matched (1:1) using propen

92 The mean (SD) age of women with no use of ART was 29.1 (4.9) years, and the age of those

93 inoma and lower liver-related mortality than no use of aspirin, without a significantly higher risk o

94 ng in a 100% intent-to-treat (ITT) rate with no use of bridging therapy.

95 st risk of psychotic disorders compared with no use of cannabis (adjusted OR 5.4, 95% CI 2.81-11.31,

96 r risk of death than those with a history of no use of cannabis.

97 f Veterans had Rapid Recovery with little or no use of care; 15% had a Steady Recovery with initially

98 uses of GPR15, CXCR6, and APJ, but little or no use of CCR2b, CCR3, CCR8, GPR1, and CXCR4.

99 glycemic control compared with infrequent or no use of CGM.

100 iance during the first 24 hours of care with no use of chest radiography, albuterol, glucocorticoids,

101 serum total cholesterol level <200 mg/dL and no use of cholesterol-lowering medication; blood pressur

102 mmercially available compression device; and no use of compressive dressing.

103 h no concurrent psychotic or manic symptoms, no use of concurrent psychotropic medications, and no cu

104 , >/= 7 clients per day (AOR, 3.3; 1.8-6.1), no use of condoms (AOR, 3.8, 2.1-7.1), and frequent alco

105 r catalyst loading and reaction temperature, no use of corrosive Bronsted acids as well as toxic azeo

106 Activity Index (CDAI) <150 [range, 0-600]), no use of corticosteroids or immunosuppressive or biolog

107 complicated small intestinal ulcers despite no use of cyclooxygenase inhibitors.

108 Two respondents reported no use of drug samples, while 4 respondents reported tak

109 with severe laryngopharyngeal disorders and no use of epinephrine.

110 -free survival curves for continuous use and no use of estrogen plus progestin crossed at about 6 yea

111 >= 20% IOP reduction from baseline; and (4) no use of glaucoma medications.

112 stin only, or nonoral products compared with no use of hormonal contraception.

113 r menses in the previous year, and to report no use of hormonal contraception.

114 2, 2019, and who had valid blood samples and no use of hormone replacement therapy within 3 months of

115 Compared with no use of hormone therapy, the hazard ratio for continuo

116 woman with a body mass index of 25 kg/m(2), no use of hypertension treatment and no history of heart

117 ge, no history of angina pectoris or asthma, no use of hypoglycemic agent, more activity level, and l

118 d 4) nonatopic with a low infection rate and no use of inhaled corticosteroids (27.6%).

119 L/min per 1.73 m(2), hemoglobin >8 g/dL, and no use of intravenous inotropes or vasopressors.

120 There is no use of isotopic labeling or chemically similar standa

121 phospholipids in the biological extract with no use of isotopic labeling.

122 s [ACQ score <= 0.75], no exacerbations, and no use of maintenance oral corticosteroids [mOCS]), and

123 The method makes no use of mass spectral fingerprints.

124 R, 2.86; 95% CI, 1.25 to 6.56) compared with no use of NSAIDs.

125 s and between 59 (78%) and 75 (85%) reported no use of opioids; 57 patients (60%) reported no days of

126 n, urban residence, low body mass index, and no use of oral contraceptives.

127 s among current exclusive e-cigarette users (no use of other tobacco products) by school level and us

128 Making no use of physical laws or co-evolutionary information,

129 s g = 0.34 [95% CI, 0.30-0.38]; I2 = 54% for no use of PRI periods; P = .92).

130 e previous year; 33.6% slaughterers reported no use of protective equipment at work.

131 r the first dose of study drug (ECR window), no use of rescue antibiotics, and patient survival.

132 se (defined as no vomiting, no retching, and no use of rescue medication) during the 25-120 h (delaye

133 nd point; a complete response (no emesis and no use of rescue medication) was a secondary end point.

134 articipants with no vomiting or retching and no use of rescue medications (a complete response) durin

135 5 on a visual analog scale of 1 to 100), and no use of rescue medications for nausea.

136 ive deficits at visit 3 were associated with no use of rituximab before visit 1 (odds ratio [OR] 4.0,

137 As compared with no use of SSRIs both before and during pregnancy, use du

138 mAb) was successfully quantified by CMS with no use of standards.

139 e control group had traditional classes with no use of standing desks or any other interference/actio

140 would result in a longer time to death than no use of supplemental oxygen among patients who had sta

141 atched cohort study, comparing SV new users (no use of SV, ACE inhibitor, ARB 6 months before) and SV

142 vider agreement regarding remission, and (4) no use of systemic corticosteroids.

143 ph nodes (hazard ratio of 2.7, P =.008), and no use of tamoxifen (hazard ratio of 3.9, P =.027) indep

144 mber of involved lymph nodes (P <.0001), and no use of tamoxifen (P =.0013).

145 ecotourism activity; others showed little to no use of the area, despite its close proximity and high

146 l bone lesions compared with those reporting no use of these medications.

147 ent (OR 2.33, 95% CI 1.55-3.55, p < 0.0001), no use of topical ice slush (OR 1.29, 95% CI 1.10-1.49,

148 response, defined as no disease activity and no use of topical steroids or systemic antibiotic treatm

149 2 (HER2) (in 15,418 patients in trials with no use of trastuzumab) was not predictive.

150 ion of milk or breakfast cereal <3 times/wk, no use of vitamin D supplements, season, urban residence

151 Compared to a unit policy of no-use of tocolysis after PPROM, a liberal or restricted

152 ncluded age, household wealth index, use (vs no use) of menstrual materials (eg, pads, tampons, or cl

153 Hz(1/2) to(14)NO and 0.53 ppbv/Hz(1/2) to(15)NO using only 45 cm active optical path.

154 volved proper balloon use and 56.0% involved no use or improper use.

155 ated with air freshener use in comparison to no use (p < 0.01), residences built since 2005 compared

156 infections among consistent users reporting no use problems.

157 ectively managed in 17, 32 and 45 units with no-use, restricted and liberal tocolysis policies for PP

158 HR of 1.49 (95% CI, 1.42-1.56) compared with no use, resulting in an increase in the 12-month absolut

159 al cells (BAECs) by measuring superoxide and NO* using spin probe 1-hydroxy-3-methoxycarbonyl-2,2,5,5

160 Compared with those reporting no use, subjects drinking > or =4 cups/day of decaffeina

161 onclude that a fluorescence determination of NO using the DAF family of probes, in combination with t

162 eadmissions, then flagged cases (PPR-Yes/PPR-No) using the 3M-PPR software.

163 Relative to no use, the lower risk of ovarian cancer associated with

164 Amperometric detection of NO using these two electrode systems shows that the sens

165 e, claimed that abstract intelligence was of no use to ancestral humans and could only be explained b

166 SRCs in pretreatment biopsies seems to be of no use to define treatment strategy or prognosis.

167 at a common feature of animal behavior is of no use to small free-swimming organisms.

168 Being of little or no use to the bacterium except during specific stages of

169 reational drug use during the past 3 months (no use, use once per week or less, or use more than once

170 cticide-treated net during travel (18.0% for no use vs 4.1% for any use; 5.10; 1.07-24.5; P = .04).

171 e more than six times per year compared with no use was 1.73 during high school/college v 1.28 at age

172 urrent use of a glucocorticoid compared with no use was 4.9 (95% confidence interval [95% CI] 2.9-8.3

173 eriod ending 2 years before diagnosis versus no use was associated with a decreased risk of bladder c

174 e plans (OR = 0.53, 95% CI: 0.35, 0.80), and no use was associated with lower odds of suicidal ideati

175 ble analyses, multivitamin use compared with no use was not associated with major CVD events (HR: 1.0

176 HT use from the perimenopausal stage versus no use was validated with prospective daily diary record

177 AD undergoing routine care, use of ChEI (vs no-use) was associated with lower risk of CKD progressio

178 7 days of aspirin use per week compared with no use were 1.07 (95% CI, 0.70 to 1.63), 0.29 (95% CI, 0

179 rapy and no use and between polypharmacy and no use were in line with the primary comparison of polyp

180 The level of drainage amylase is of no use, whereas univariate analysis identified underlyin

181 aOR] 3.11, 95% CI 2.41-4.03 for >=7 h use vs no use), with similar associations for e-cigarettes (aOR

182 no use) within 5 km of the home during the second trimes